Assessing Optimal XRB Initiation Points in Jail
Opioid Use Disorder
About this trial
This is an interventional treatment trial for Opioid Use Disorder
Eligibility Criteria
Inclusion Criteria: Incarcerated men able to provide written informed consent in English.* Unsentenced. Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days. Minimum anticipated jail stay is 4 days. Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated). Exclusion Criteria: Sentenced. Allergy, hypersensitivity or medical contraindication to either medication. Chronic pain requiring opioid pain management or other contraindicated medications.
Sites / Locations
- NYU Langone Health - 180 Madison Ave
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Transition to Extended-Release Buprenorphine (XRB)
Sublingual Buprenorphine (SLB) Maintenance
Participants randomized to transition to treatment with XRB.
Participants randomized to remain on-treatment with SLB.